Agarwood and the "Three Highs": The Most Honest Line in 48 Papers

Can agarwood help manage the "three highs" (high blood sugar, high blood lipids, and high blood pressure)? The 48 papers our center has compiled (2008–2026) give an answer in two halves: the laboratory-level evidence genuinely exists, while human clinical trials remain at zero. Many sales pitches will not tell you that second half.

1. The Most Authoritative Summary

A 2024 scoping review from Malaysia published in Molecules (PMC11597494) condensed the current state of evidence on agarwood in metabolic health into one sentence: "no clinical trials, but promising in vitro and in vivo studies." Everyone concerned with this topic should remember that exact wording—it is the current ceiling of the evidence.

2. What the Laboratory Evidence Looks Like

The review summarized four major mechanisms of action: inhibition of α-glucosidase, α-amylase, and lipase activity; promotion of adiponectin secretion; reduction of oxidative stress; and, in animal models, blood glucose lowering, anti-dyslipidemic, anti-obesity, and organ-protective effects. As for active constituents, chromones (especially 2-(2-phenylethyl)chromones) are the main active components for α-glucosidase inhibition and PPARγ agonism, with sesquiterpenes also contributing. The species tested covered four, including Aquilaria sinensis and Aquilaria malaccensis, and the plant parts included wood, leaves, bark, fruit peel, and branches—note that the latter four are not among the legally defined medicinal parts in the Chinese Pharmacopoeia (agarwood refers only to resin-bearing wood), a distinction that must be made when citing them.

3. Records on the Chinese-Language Literature Side

A 2020 review of the pharmacology of domestically produced agarwood in the Shandong Journal of Traditional Chinese Medicine (46 references) listed blood glucose lowering as one of the five major activities of domestic agarwood; a 2024 monograph edited by Ni Qing of the Endocrinology Department of Guang'anmen Hospital, China Academy of Chinese Medical Sciences, records: "after 15 consecutive days of intragastric administration, fasting blood glucose values in mice in the agarwood-treated group were significantly reduced," and also records experiments on improving myocardial ischemia and early blood pressure reduction. But the compilers of the collection honestly point out: these records are summaries from reference works, without original data cited, and cannot be used as primary evidence.

4. How We Use This Evidence

Two rules. First, when citing any in vitro or animal data, simultaneously state the tier limitation of "no human clinical trials"—this is not only rigor but also honesty toward buyers. Second, agarwood cigarette threads, incense sticks, and incense powder are not blood glucose-lowering or lipid-lowering drugs; readers with metabolic problems should follow medical advice and receive standard treatment. Incense products can be the cultural part of your life, but they cannot be your treatment plan.

This article is a review of research literature, for academic reference only, and does not constitute medical advice. For related health issues, please follow medical advice; when using agarwood incense, maintain ventilation and control the duration. The bibliographic information in this article was compiled by the Wubaiyi Agarwood Research Center and the Zhongke Agarwood Standard Technology Research Institute's "Agarwood Research Literature Collection" series (October 2026); please verify the original literature before citing specific data.